Celcuity Appoints Oncology Commercialization Expert Charles Romp to Board
CELC has more than doubled off its 52-week low of $7.575.
Summary
Celcuity Inc. appointed Charles Romp, an experienced oncology commercialization executive, to its Board of Directors, signaling a strategic focus on preparing for the potential launch of its lead drug candidate.
Key Events · Executive and Board Changes · CELC
-
New Director Appointed
Charles (Chip) R. Romp was appointed to the Board of Directors, effective February 11, 2026, increasing the board size from seven to eight members.
-
Strategic Oncology Expertise
Mr. Romp brings over 25 years of experience in the pharmaceutical industry, with a strong focus on leading sales and commercial organizations in oncology, including roles at Seagen and Genentech.
-
Support for Gedatolisib Commercialization
The appointment is highlighted by the CEO as providing 'valuable insight' as the company advances its programs and prepares for the potential approval and launch of gedatolisib, its lead oncology therapeutic candidate.
-
Standard Director Compensation
Mr. Romp will receive an annual cash retainer of $50,000 and an annual equity award with a fair market value of $100,000, along with a pro-rated grant of 215 restricted shares upon appointment.
Analysis · CELC · Industrial Applications And Services
Celcuity Inc. has strategically strengthened its Board of Directors with the appointment of Charles Romp, an industry veteran with over 25 years of experience in oncology commercialization. This move is particularly significant for a clinical-stage biotechnology company like Celcuity, as it prepares for the potential approval and launch of its lead therapeutic candidate, gedatolisib, later this year. Romp's expertise from companies like Seagen and Genentech will be invaluable in guiding the company's commercial strategy and market penetration in the highly competitive oncology space.
At the time of this filing, CELC was trading at $104.87 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $7.58 to $120.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.